Research progress of pyruvate kinase type M2 in hepatocellular carcinoma / 中华肝脏病杂志
Chinese Journal of Hepatology
;
(12): 117-120, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-935921
ABSTRACT
Primary hepatocellular carcinoma is one of the most common high-grade malignant tumors in the world. Its incidence ranks fifth among malignant tumors in China, and various therapeutic measures have poor curative effect. Pyruvate kinase type M2 is a key enzyme in the glycolytic pathway, and its abnormal expression in liver cancer is closely related to the proliferation, metastasis, diagnosis, treatment, prognosis, as well as drug and radiation resistance. Therefore, multi-pathway targeted regulation of pyruvate kinase type M2 use is expected to become a new direction for the treatment of primary liver cancer.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Pronóstico
/
Piruvato Quinasa
/
China
/
Carcinoma Hepatocelular
/
Neoplasias Hepáticas
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
País/Región como asunto:
Asia
Idioma:
Chino
Revista:
Chinese Journal of Hepatology
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS